Add to ORKGThe advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-static renal cell carcinoma (mRCC) had a substan-tial impact on the treatment landscape in mRCC
JOURNAL ARTICLE;The emergence of novel drugs corresponds with the determination of the effectiveness...
JOURNAL ARTICLE;The emergence of novel drugs corresponds with the determination of the effectiveness...
JOURNAL ARTICLE;The emergence of novel drugs corresponds with the determination of the effectiveness...
The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...
The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...
Historically, the median survival of patients with metastatic renal cell carcinoma (MRCC) was 10 mon...
Background: Targeted agents were introduced over past years because of better understanding of oncog...
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...
The standards of treatment for metastatic renal cell carcinoma (mRCC) have changed significantly fro...
Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents tar...
International audienceCONTEXT: Metastatic renal cell carcinoma (mRCC) has long been treated only by ...
Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the re...
Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal...
Following approval of the oral, multitargeted tyrosine kinase inhibitor sunitinib malate for the tre...
JOURNAL ARTICLE;The emergence of novel drugs corresponds with the determination of the effectiveness...
JOURNAL ARTICLE;The emergence of novel drugs corresponds with the determination of the effectiveness...
JOURNAL ARTICLE;The emergence of novel drugs corresponds with the determination of the effectiveness...
The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...
The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...
Historically, the median survival of patients with metastatic renal cell carcinoma (MRCC) was 10 mon...
Background: Targeted agents were introduced over past years because of better understanding of oncog...
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...
Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The...
The standards of treatment for metastatic renal cell carcinoma (mRCC) have changed significantly fro...
Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents tar...
International audienceCONTEXT: Metastatic renal cell carcinoma (mRCC) has long been treated only by ...
Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the re...
Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal...
Following approval of the oral, multitargeted tyrosine kinase inhibitor sunitinib malate for the tre...
JOURNAL ARTICLE;The emergence of novel drugs corresponds with the determination of the effectiveness...
JOURNAL ARTICLE;The emergence of novel drugs corresponds with the determination of the effectiveness...
JOURNAL ARTICLE;The emergence of novel drugs corresponds with the determination of the effectiveness...